Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Larissa J. Vos"'
Autor:
John Walker, Anil Abraham Joy, Larissa J. Vos, Trevor H. Stenson, John R. Mackey, Juan Jovel, Dina Kao, Karen L. Madsen, Gane Ka-Shu Wong
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-15 (2023)
Abstract Background Early-stage breast cancer patients treated with chemotherapy risk the development of metabolic disease and weight gain, which can result in increased morbidity and reduced quality of life in survivorship. We aimed to analyze chang
Externí odkaz:
https://doaj.org/article/e47f1366226642289883281862157248
Autor:
Ana Lopez-Campistrous, Esther Ekpe Adewuyi, Matthew G.K. Benesch, Yi Man Ko, Raymond Lai, Aducio Thiesen, Jay Dewald, Peng Wang, Karen Chu, Sunita Ghosh, David C. Williams, Larissa J. Vos, David N. Brindley, Todd P.W. McMullen
Publikováno v:
EBioMedicine, Vol 12, Iss C, Pp 86-97 (2016)
Dedifferentiation of follicular cells is a central event in resistance to radioactive iodine and patient mortality in papillary thyroid carcinoma (PTC). We reveal that platelet derived growth factor receptor alpha (PDGFRα) specifically drives dediff
Externí odkaz:
https://doaj.org/article/c5c4da49361e49e0a54a8697243b501a
Publikováno v:
PLoS ONE, Vol 6, Iss 2 (2011)
Externí odkaz:
https://doaj.org/article/6c1b6df653ad4bda9cb39f41180733f0
Autor:
Keith Tankel, Marc Mackenzie, Larissa J. Vos, Susan Chafe, Lee-Anne Polkosnik, John Amanie, Nadeem Pervez, John R. Mackey, Zsolt Gabos, Sunita Ghosh, S. Horsman, S. Sabri, Matthew Parliament, Kent Powell, B. S. Abdulkarim, Heather Warkentin, Kurian Joseph
Publikováno v:
Clinical Oncology. 33:30-39
Skin toxicity is a common adverse effect of breast radiotherapy. We investigated whether inverse-planned intensity-modulated radiotherapy (IMRT) would reduce the incidence of skin toxicity compared with forward field-in-field breast IMRT (FiF-IMRT) i
Autor:
Zainab Abdelaziz, Arthur Lui, John R. Mackey, Jennifer L. Spratlin, Dimas Yusuf, Larissa J. Vos, Sunita Ghosh
Publikováno v:
JCO precision oncology. 3
Purpose Gemcitabine, the primary drug for the treatment of pancreatobiliary cancer (PBC), requires human equilibrative nucleoside transporter 1 (hENT1) to enter cells. High tumoral hENT1 expression has been linked with improved survival among patient
Autor:
Michael H. Wang, Nadeem Pervez, Brita Danielson, John Amanie, Sunita Ghosh, Robert Pearcey, Don Yee, Colin Field, Samir Patel, Albert Murtha, Matthew Parliament, B. Gino Fallone, Larissa J. Vos, Nawaid Usmani
Publikováno v:
Practical radiation oncology. 11(5)
Purpose Hypofractionated radiation therapy (HFRT) may offer treatment advantages for patients with prostate cancer. However, HFRT may also increase the risk of gastrointestinal (GI) or genitourinary (GU) toxicity compared with conventionally fraction
Autor:
Sarah F. Cook, Anil A. Joy, Ann Vlahadamis, Karen King, Vijaya L. Damaraju, Avalyn Stanislaus, Larissa J. Vos, Michael B. Sawyer, Judith Meza-Junco, Edith Pituskin, Sanraj Basi, Robert R. Bies, Sambasivarao Damaraju, John R. Mackey
Publikováno v:
Clinical breast cancer. 21(5)
Background Epirubicin is metabolized by uridine glucuronosyltransferase 2B7 (UGT2B7). Patients homozygous for the minor allele (CC) in the UGT2B7 -161 promoter polymorphism have lower clearance and significantly higher rates of leukopenia compared to
Autor:
Larissa J. Vos, Kurian Joseph, Kayla Mah, Carole R Chambers, Veronica Alba, Ericka Wiebe, Hong-Wei Liu, Keith Tankel, Sasha Lupichuk, Karen King, Sunita Ghosh, Cara Au, Aswin George Abraham, Sarah Zebak, Susan Chafe, Zsolt Gabos
Publikováno v:
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 154
The relative benefit of adjuvant radiotherapy (RT) alone in older women with low-risk early breast cancer (EBC) remains unclear. It is hypothesized that adjuvant RT-alone can improve outcomes of older patients with low-risk EBC, similar to endocrine
Autor:
Brock Debenham, Hadi Seikaly, Naresh Jha, Jeffrey Harris, Larissa J. Vos, Sunita Ghosh, Rufus Scrimger, Daniel A. O’Connell
Publikováno v:
Head & Neck. 40:2353-2361
Background Xerostomia is a debilitating side effect of radiotherapy for head and neck cancer. Combining surgical submandibular-gland transfer (SMGT) with intensity-modulated radiotherapy (IMRT) may provide greater protection of salivary function. Met
Autor:
Arthur Lui, Rakesh Goel, Hagen F. Kennecke, M. Vickers, Jose Gerard Monzon, Larissa J. Vos, Jennifer L. Spratlin, Horia Marginean, J. Maroun, Christine Brezden-Masley, Anthony Fields, Sunita Ghosh, Karen E. Mulder
Publikováno v:
Investigational New Drugs. 36:674-682
Purpose Chemotherapy remains the primary treatment for metastatic gastric/GEJ cancer but optimal agents and schedule remain controversial. This study examined the safety and efficacy of first-line Irinotecan, capecitabine (Xeloda®), and Oxaliplatin